People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

HALIFAX – Nova Scotia physicians and other sexual health experts who are calling on the provincial government to fund birth ...

Roughly $12 million worth of HIV-prevention drugs and contraceptives purchased by the U.S. Agency for International ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...